newsfilter
← Latest News
GlobeNewswire·

Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied